Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Phase 3

Active, not recruiting

• Conditions: Primary Biliary Cirrhosis
• Interventions: Drug: Seladelpar 5 mg Capsule; Drug: Seladelpar 10 mg Capsule

• Registration Number: NCT03301506
• Lead Sponsor: Gilead Sciences

Brief Summary

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Detailed Description

Primary:

To evaluate the long-term safety and tolerability of seladelpar

Secondary:

* To evaluate the long-term efficacy of seladelpar

* To evaluate the effect of seladelpar on patient-reported outcomes (pruritus)

Study Timeline

• Study First Submitted: 2017-09-26
• Study First Submitted QC: 2017-09-29
• Study First Posted: 2017-10-04
• Study Start: 2017-12-12
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-15
• Last Update Posted: 2025-04-17
• Primary Completion: 2028-11
• Study Completion: 2028-11

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Must have given written informed consent (signed and dated)
2. Participated in a PBC study with seladelpar
3. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose

Exclusion Criteria

Exclusion criteria are only applicable for subjects with a seladelpar interruption greater than 4 weeks prior to Day 1 of this study and for subjects who participated in CB8025-21838 irrespective of seladelpar interruption.

1. Treatment-related adverse event (AE) leading to study drug discontinuation in a previous PBC study with seladelpar

2. A medical condition, other than PBC, that in the Investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer, any active infection)

3. AST or ALT above 3 × the upper limit of normal (ULN)

4. Total bilirubin above 2 × ULN

5. MELD score ≥ 12. For subjects on anticoagulation medication, evaluation of the baseline INR, in concert with any current dose adjustments in anti-coagulant medications, will be taken into account when calculating this score. This will be done in consultation with the medical monitor.

6. Evidence of advanced PBC as defined by the Rotterdam criteria: albumin below 1× the lower limit of normal (LLN) AND total bilirubin above 1 × ULN)

7. eGFR ≤45 mL/min/1.73 m2 (calculated by MDRD formula)

8. Auto-immune hepatitis

9. Primary sclerosing cholangitis

10. Known history of alpha-1-antitrypsin deficiency

11. Known history of chronic viral hepatitis

12. For females, pregnancy or breast-feeding

13. Use of colchicine, methotrexate, azathioprine, or long-term use of systemic steroids (e.g. prednisone, prednisolone, budesonide) (>2 weeks) within 2 months prior to Screening

14. Current use of fibrates or use of fibrates within 3 months prior to Screening

15. Current use of obeticholic acid or use of obeticholic acid within 3 months prior to Screening

16. Use of an experimental or unapproved treatment for PBC within 3 months prior to Screening

17. History of malignancy diagnosed or treated, actively or within 2 years, or active evaluation for malignancy; localized treatment of squamous or non-invasive basal cell skin cancers and cervical carcinoma in-situ is allowed if appropriately treated prior to Screening

18. Treatment with any other investigational therapy or medical device within 30 days or within 5 half-lives, whatever is longer, prior to Screening

19. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

20. Immunosuppressant therapies (e.g., cyclosporine, tacrolimus, anti-TNF or other immunosuppressive biologics)

21. Other medications that effect liver or GI functions such as absorption of medications or the roux-en-y gastric bypass procedure may be prohibited and should be discussed with the medical monitor on a case-by-case basis

22. Positive for:

    1. Hepatitis B, defined as the presence of hepatitis B surface antigen
    2. Hepatitis C, defined as the presence of hepatitis C virus ribonucleic acid (RNA)
    3. Human immunodeficiency virus (HIV) antibody

23. Active COVID-19 infection during screening

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Seladelpar 5 mg Capsules	Seladelpar 5 mg Capsule	-
Seladelpar 10 mg Capsule	Seladelpar 10 mg Capsule	-

Primary Outcome Measures

Name	Time	Method
Treatment emergent adverse events (TEAEs) (National Cancer Institute {NCI} Common Terminology Criteria for Adverse Events {CTCAE} Version 5.0), biochemistry and hematology results	Through study completion, up to 60 Months

Secondary Outcome Measures

Name	Time	Method
Ascites	60 Months	Occurrence of overall ascites requiring treatment
Laboratory Value: Gamma-glutamyl Transferase (GGT)	Through study completion, up to 60 Months	Gamma-glutamyl Transferase (GGT)
Hospitalization for variceal bleeding	60 Months	Hospitalization for new onset, or recurrence, of variceal bleeding
Hospitalization for hepatic encephalopathy	60 Months	Hospitalization for new onset, or recurrence, hepatic encephalopathy (as defined by a West Haven score ≥ 2)
Normalization of ALP	60 Months	Proportion of subjects with normalization of ALP
Laboratory Value: Bilirubin - Unconjugated Bilirubin	Through study completion, up to 60 Months	Bilirubin - Unconjugated Bilirubin
Laboratory Value: Serum Alkaline Phosphatase (ALP)	Through study completion, up to 60 Months	Serum Alkaline Phosphatase (ALP)
Laboratory Value: Alanine Aminotransferase (ALT)	Through study completion, up to 60 Months	Alanine Aminotransferase (ALT)
Change in MELD	60 Months	MELD score ≥ 15 for at least 2 consecutive visits
Hospitalization for spontaneous bacterial peritonitis	60 Months	Hospitalization for new onset, or recurrence, spontaneous bacterial peritonitis (confirmed by culture from diagnostic paracentesis)
Response on composite endpoint	60 Months	Total bilirubin
Laboratory Value: Aspartate Aminotransferase (AST)	Through study completion, up to 60 Months	Aspartate Aminotransferase (AST)
Laboratory Value: Bilirubin - Total Bilirubin	Through study completion, up to 60 Months	Bilirubin - Total Bilirubin
Liver transplantation	60 Months	Occurrence of overall liver transplantation
Laboratory Value: Bilirubin - Conjugated Bilirubin	Through study completion, up to 60 Months	Bilirubin - Conjugated Bilirubin
Death	60 Months	Occurrence of overall death

Trial Locations

Locations (108)

Arkansas Diagnostic Center; 🇺🇸 Little Rock, Arkansas, United States

Stanford University School of Medicine; 🇺🇸 Palo Alto, California, United States

California Liver Research Institute; 🇺🇸 Pasadena, California, United States

University of California Davis Medical Center; 🇺🇸 Sacramento, California, United States

California Pacific Medical Center; 🇺🇸 San Francisco, California, United States

University of Colorado - Denver - PPDS; 🇺🇸 Aurora, Colorado, United States

Yale University School of Medicine; 🇺🇸 New Haven, Connecticut, United States

Covenant Research Fort Myers; 🇺🇸 Fort Myers, Florida, United States

Florida Digestive Health Specialist; 🇺🇸 Lakewood Ranch, Florida, United States

University of Miami Miller School of Medicine; 🇺🇸 Miami, Florida, United States

Scroll for more (98 remaining)